Your browser is no longer supported. Please, upgrade your browser.
Settings
AGIO Agios Pharmaceuticals, Inc. daily Stock Chart
AGIO [NASD]
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.81 Insider Own2.50% Shs Outstand58.17M Perf Week0.73%
Market Cap5.30B Forward P/E- EPS next Y-5.50 Insider Trans55.78% Shs Float50.17M Perf Month-8.53%
Income-339.30M PEG- EPS next Q-1.55 Inst Own99.84% Short Float9.81% Perf Quarter5.33%
Sales41.30M P/S128.26 EPS this Y-33.20% Inst Trans0.14% Short Ratio14.48 Perf Half Y30.29%
Book/sh15.54 P/B5.86 EPS next Y14.00% ROA-43.80% Target Price99.25 Perf Year59.11%
Cash/sh13.45 P/C6.77 EPS next 5Y- ROE-61.70% 52W Range51.62 - 99.82 Perf YTD59.28%
Dividend- P/FCF- EPS past 5Y3.40% ROI-85.40% 52W High-8.78% Beta2.02
Dividend %- Quick Ratio10.70 Sales past 5Y11.40% Gross Margin- 52W Low76.40% ATR3.52
Employees382 Current Ratio10.70 Sales Q/Q-16.20% Oper. Margin- RSI (14)55.80 Volatility4.97% 4.08%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.20% Profit Margin- Rel Volume1.28 Prev Close91.18
ShortableYes LT Debt/Eq0.00 EarningsAug 07 BMO Payout- Avg Volume339.91K Price91.06
Recom2.00 SMA203.03% SMA501.43% SMA20018.77% Volume434,921 Change-0.13%
May-23-18Initiated Citigroup Buy $117
Apr-11-18Reiterated Credit Suisse Outperform $80 → $95
Feb-15-18Reiterated SunTrust Buy $80 → $101
Feb-15-18Reiterated Needham Buy $72 → $86
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Aug-02-17Upgrade Leerink Partners Mkt Perform → Outperform $80
Jun-26-17Downgrade Janney Buy → Neutral
Jan-17-17Upgrade Oppenheimer Perform → Outperform
Oct-24-16Initiated Needham Buy $60
Jun-13-16Upgrade JP Morgan Neutral → Overweight
May-18-16Reiterated SunTrust Buy $57 → $65
May-18-16Reiterated Sun Trust Rbsn Humphrey Buy $57 → $65
Mar-30-16Initiated Sun Trust Rbsn Humphrey Buy $57
Jan-21-16Initiated Credit Suisse Outperform
Dec-07-15Downgrade Leerink Partners Outperform → Mkt Perform
Nov-09-15Reiterated ROTH Capital Neutral $114 → $75
Jul-22-15Initiated Northland Capital Outperform $132
Jun-15-15Reiterated Canaccord Genuity Hold $103 → $93
Jul-20-18 02:46PM  Cambridge's Agios wins FDA approval for second cancer drug American City Business Journals
10:59AM  FDA approves Agios Pharmaceuticals leukemia drug Reuters
10:45AM  FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation GlobeNewswire
Jun-29-18 07:50AM  Analysis: Positioning to Benefit within Biglari, Trustmark, Allscripts Healthcare Solutions, Agios Pharmaceuticals, Roadrunner Transportation, and OSI Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-27-18 11:32AM  Agios Out-Licenses China Rights to Leukemia Drug Tibsovo Zacks
Jun-26-18 08:16AM  BRIEF-Agios And CStone Pharmaceuticals Announce Exclusive Collaboration And License Agreement To Develop And Commercialize Ivosidenib In Greater China Reuters -5.30%
08:00AM  Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China GlobeNewswire
Jun-21-18 08:39AM  Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street Benzinga
Jun-20-18 03:54AM  Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug Zacks
Jun-18-18 07:00AM  Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused GlobeNewswire
Jun-05-18 12:04PM  Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason InvestorPlace
Jun-04-18 09:00AM  New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients GlobeNewswire
05:43AM  Agios Pharmaceuticals (AGIO) Up 13.4% Since Earnings Report: Can It Continue? Zacks
Jun-02-18 04:05PM  Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent GlobeNewswire
Jun-01-18 04:15PM  Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors GlobeNewswire
08:30AM  Today's Research Reports on Trending Tickers: Tesaro and Agios Pharmaceuticals ACCESSWIRE
08:16AM  Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO Benzinga
May-31-18 04:04PM  Investors Should Own Agios For 'The Next Several Years,' Analyst Says Benzinga
May-30-18 03:17PM  Agios Pharmaceuticals Has Emerged From a 2-Year Base Pattern TheStreet.com
May-24-18 04:18PM  Agios (AGIO) Progressing Well on Pipeline Amid Competition Zacks
May-17-18 07:50AM  Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-16-18 05:02PM  Agios to Present New Clinical Data from its IDH Programs at ASCO GlobeNewswire
May-07-18 03:28PM  Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss Zacks
May-04-18 07:42AM  Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss Zacks
07:09AM  Agios Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day GlobeNewswire
Apr-30-18 11:37AM  Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings? Zacks
Apr-27-18 07:00AM  Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018 GlobeNewswire
Apr-18-18 09:58AM  Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline Zacks
Apr-16-18 08:17AM  The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte Zacks
Apr-13-18 09:33AM  Pharma M&A Active This Week: 4 Potential Buyout Targets Zacks
Apr-11-18 07:00AM  Agios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018 GlobeNewswire
Apr-10-18 11:23AM  Agios Pharmaceuticals Shares Rise on Buyout Speculation Zacks
Apr-09-18 04:32PM  Why Alcoa, Merck, and Agios Pharmaceuticals Jumped Today Motley Fool +9.26%
Apr-02-18 06:00AM  3 Hot Biotech Stocks Facing Sharp Declines Investopedia -9.97%
Mar-21-18 07:30AM  Wired News Agios Pharmaceuticals Doses First Patient in AG-270 Phase-1 Dose-Escalation Trial in MTAP-Deleted Tumors ACCESSWIRE
Mar-19-18 07:01AM  Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion GlobeNewswire
Mar-05-18 07:01AM  Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018 GlobeNewswire
Mar-02-18 07:30AM  Research Report Identifies AutoZone, Highwoods Properties, Virtu Financial, Genocea Biosciences, LGI Homes, and Agios Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-16-18 09:56AM  FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review Zacks
Feb-15-18 11:58AM  FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation GlobeNewswire
11:38AM  Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y Zacks
03:31AM  Edited Transcript of AGIO earnings conference call or presentation 14-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
Feb-14-18 08:24AM  Agios (AGIO) Q4 Loss Wider than Expected; Sales Miss Zacks
07:09AM  Agios Pharmaceuticals reports 4Q loss Associated Press
07:01AM  Agios Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
06:15AM  Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-09-18 11:20AM  Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store? Zacks
Feb-07-18 12:57PM  Why Agios Pharmaceuticals Shares Jumped 37.8% in January Motley Fool
Jan-31-18 04:01PM  Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018 GlobeNewswire
Jan-23-18 04:01PM  Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire
08:00AM  Celgene's Investments Are Soaring Motley Fool
Jan-19-18 12:56PM  Agios sizes up funding needs Reuters
10:59AM  Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year Zacks
Jan-18-18 08:43PM  Agios Announces Pricing of $475 Million Public Offering of Common Stock GlobeNewswire
Jan-17-18 04:01PM  Agios Announces Proposed Offering of Common Stock GlobeNewswire
Jan-16-18 08:06AM  See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. Markit -8.40%
Jan-12-18 08:10AM  Todays Research Reports on Stocks to Watch: Agios Pharmaceuticals, Inc. and Ironwood Pharmaceuticals, Inc. ACCESSWIRE
Jan-11-18 03:00AM  Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 81 RS Rating Investor's Business Daily +7.72%
Jan-10-18 05:20PM  How Did Bioverativ Perform in 3Q17? Market Realist +6.01%
03:49PM  Analysts Recommendations for Bioverativ in January 2018 Market Realist
Jan-09-18 08:02AM  See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. Markit +5.31%
Jan-08-18 02:02PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO Business Wire
08:03AM  See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. Markit
07:01AM  Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value GlobeNewswire
Jan-05-18 08:30AM  Market Trends Toward New Normal in Agios Pharmaceuticals, Virtu Financial, Tableau Software, Graco, Kadmon, and Titan International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-04-18 09:17AM  How Analysts Rated Jazz Pharmaceuticals in December Market Realist
Jan-02-18 07:30AM  Agios to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 GlobeNewswire
Dec-29-17 11:26AM  ETFs with exposure to Agios Pharmaceuticals, Inc. : December 29, 2017 Capital Cube -5.69%
Dec-28-17 07:00AM  Wired News - Agios Pharma Submitted NDA for Ivosidenib for Treatment of Patients with Relapsed/Refractory AML and IDH1 Mutation ACCESSWIRE
Dec-27-17 09:08AM  Agios (AGIO) Files NDA for Leukemia Candidate in the U.S. Zacks
07:04AM  Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo Zacks
Dec-26-17 03:25PM  Agios lines up another potential FDA nod with new leukemia drug American City Business Journals
07:30AM  Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation GlobeNewswire
Dec-11-17 04:41PM  Agios targeting cancer medicines CNBC Videos
04:05PM  Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation GlobeNewswire
04:01PM  Promising responses seen with Agios leukemia drug in study Reuters
04:00PM  New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML GlobeNewswire
Dec-10-17 09:25PM  Cambridge biotechs among big winners at ASH blood disease conference American City Business Journals
06:00PM  Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency GlobeNewswire
Dec-05-17 07:00AM  Agios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors GlobeNewswire
03:00AM  IBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Relative Price Strength Investor's Business Daily
Nov-27-17 11:51AM  ETFs with exposure to Agios Pharmaceuticals, Inc. : November 27, 2017 Capital Cube
08:50AM  [$$] VC Focus: Once Rare, Health-Care Megarounds Grow More Common The Wall Street Journal
Nov-21-17 06:01AM  Fighting Cancer One Patient At A Time Forbes
Nov-20-17 03:42PM  Agios Posts New Data on Glioma Candidate from Dose Expansion Zacks
Nov-17-17 07:05AM  Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma GlobeNewswire
Nov-16-17 11:05AM  ETFs with exposure to Agios Pharmaceuticals, Inc. : November 16, 2017 Capital Cube
Nov-09-17 07:55AM  Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 9, 2017 Capital Cube
Nov-06-17 11:01AM  ETFs with exposure to Agios Pharmaceuticals, Inc. : November 6, 2017 Capital Cube
Nov-03-17 09:58AM  Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Exelixis, Inc. and Agios Pharmaceuticals ACCESSWIRE
Nov-02-17 06:57PM  Edited Transcript of AGIO earnings conference call or presentation 1-Nov-17 12:00pm GMT Thomson Reuters StreetEvents
12:08PM  Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y Zacks
Nov-01-17 09:32AM  Agios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting GlobeNewswire
07:42AM  Agios (AGIO) Q3 Loss Narrower than Expected, Sales Beat Zacks
07:08AM  Agios Pharmaceuticals reports 3Q loss Associated Press
07:00AM  Agios Reports Third Quarter 2017 Financial Results GlobeNewswire
06:00AM  Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-31-17 12:03PM  Agios Pharmaceuticals, Inc. Value Analysis (NASDAQ:AGIO) : October 31, 2017 Capital Cube
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bowden ChristopherChief Medical OfficerJul 10Option Exercise35.162,00070,3202,924Jul 12 04:14 PM
Bowden ChristopherChief Medical OfficerJul 10Sale86.762,000173,512924Jul 12 04:14 PM
Alenson CarmanPrincipal Accounting OfficerJul 09Option Exercise52.2927214,223272Jul 11 04:23 PM
Alenson CarmanPrincipal Accounting OfficerJul 09Sale84.9427223,1040Jul 11 04:23 PM
Biller ScottChief Scientific OfficerJul 05Option Exercise9.053,00027,15060,196Jul 09 04:08 PM
Biller ScottChief Scientific OfficerJul 05Sale83.503,000250,50357,196Jul 09 04:08 PM
Hoerter Steven L.Chief Commercial OfficerJun 22Option Exercise39.762,05081,5082,050Jun 26 04:02 PM
Hoerter Steven L.Chief Commercial OfficerJun 22Sale97.582,050200,0390Jun 26 04:02 PM
Foster-Cheek Kaye IDirectorJun 14Option Exercise50.739,000456,57011,200Jun 18 04:05 PM
Foster-Cheek Kaye IDirectorJun 14Sale93.559,000841,9262,200Jun 18 04:05 PM
Bowden ChristopherChief Medical OfficerJun 12Option Exercise35.162,00070,3202,881Jun 14 04:23 PM
Bowden ChristopherChief Medical OfficerJun 12Sale92.892,000185,786881Jun 14 04:23 PM
Biller ScottChief Scientific OfficerJun 05Option Exercise9.053,00027,15060,196Jun 07 04:02 PM
Biller ScottChief Scientific OfficerJun 05Sale93.373,000280,10157,196Jun 07 04:02 PM
Schenkein David PChief Executive OfficerJun 01Option Exercise0.4813,0006,28013,000Jun 05 04:10 PM
Schenkein David PChief Executive OfficerJun 01Sale95.3513,0001,239,6080Jun 05 04:10 PM
Schenkein David PChief Executive OfficerMay 30Option Exercise0.3945,62617,67545,626Jun 01 04:08 PM
Schenkein David PChief Executive OfficerMay 30Sale90.0745,6264,109,5340Jun 01 04:08 PM
Biller ScottChief Scientific OfficerMay 23Option Exercise31.6415,177480,20072,373May 29 06:11 AM
Hoerter Steven L.Chief Commercial OfficerMay 23Option Exercise39.762,05081,5082,050May 29 06:14 AM
Schenkein David PChief Executive OfficerMay 23Option Exercise0.3049,37414,93649,374May 29 06:17 AM
Biller ScottChief Scientific OfficerMay 23Sale90.0015,1771,365,93057,196May 29 06:11 AM
Hoerter Steven L.Chief Commercial OfficerMay 23Sale85.762,050175,8080May 29 06:14 AM
Schenkein David PChief Executive OfficerMay 23Sale90.4049,3744,463,5240May 29 06:17 AM
Bowden ChristopherChief Medical OfficerMay 08Option Exercise35.162,00070,3202,881May 10 04:00 PM
Bowden ChristopherChief Medical OfficerMay 08Sale81.382,000162,760881May 10 04:00 PM
Biller ScottChief Scientific OfficerMay 07Option Exercise9.053,00027,15060,196May 08 04:08 PM
Biller ScottChief Scientific OfficerMay 07Sale81.813,000245,43057,196May 08 04:08 PM
Schenkein David PChief Executive OfficerMay 01Option Exercise0.3013,0003,93313,000May 03 04:07 PM
Schenkein David PChief Executive OfficerMay 01Sale83.0413,0001,079,5010May 03 04:07 PM
Hoerter Steven L.Chief Commercial OfficerApr 23Option Exercise39.762,05081,5082,050Apr 25 04:12 PM
Hoerter Steven L.Chief Commercial OfficerApr 23Sale85.952,050176,1980Apr 25 04:12 PM
Bowden ChristopherChief Medical OfficerApr 12Option Exercise35.162,00070,3202,881Apr 16 04:01 PM
Bowden ChristopherChief Medical OfficerApr 12Sale85.102,000170,190881Apr 16 04:01 PM
Biller ScottChief Scientific OfficerApr 05Option Exercise9.053,00027,15060,196Apr 09 04:09 PM
Biller ScottChief Scientific OfficerApr 05Sale75.203,000225,60757,196Apr 09 04:09 PM
Schenkein David PChief Executive OfficerApr 02Option Exercise0.3013,0003,93313,000Apr 04 04:03 PM
Schenkein David PChief Executive OfficerApr 02Sale77.7213,0001,010,3570Apr 04 04:03 PM
Biller ScottChief Scientific OfficerMar 28Option Exercise2.324,1379,61157,196Mar 30 04:18 PM
Hoerter Steven L.Chief Commercial OfficerMar 22Option Exercise39.762,05081,5082,050Mar 26 04:01 PM
Hoerter Steven L.Chief Commercial OfficerMar 22Sale84.652,050173,5330Mar 26 04:01 PM
Foster-Cheek Kaye IDirectorMar 19Option Exercise47.336,800321,8449,000Mar 21 04:04 PM
Foster-Cheek Kaye IDirectorMar 19Sale81.976,800557,3962,200Mar 21 04:04 PM
Scadden DavidDirectorMar 16Buy83.4420016,688571Mar 20 04:43 PM
Bowden ChristopherChief Medical OfficerMar 14Option Exercise35.162,00070,3202,881Mar 16 04:50 PM
Bowden ChristopherChief Medical OfficerMar 14Sale82.332,000164,661881Mar 16 04:50 PM
Biller ScottChief Scientific OfficerMar 05Option Exercise9.053,00027,15056,059Mar 07 04:10 PM
Biller ScottChief Scientific OfficerMar 05Sale83.083,000249,22953,059Mar 07 04:10 PM
Schenkein David PChief Executive OfficerMar 01Option Exercise0.3013,0003,93313,000Mar 05 04:32 PM
Schenkein David PChief Executive OfficerMar 01Sale81.0913,0001,054,2180Mar 05 04:32 PM
Foster-Cheek Kaye IDirectorFeb 26Option Exercise47.332,200104,1262,200Feb 28 04:02 PM
Hoerter Steven L.Chief Commercial OfficerFeb 22Option Exercise39.762,05081,5082,050Feb 26 04:45 PM
Hoerter Steven L.Chief Commercial OfficerFeb 22Sale78.632,050161,1920Feb 26 04:45 PM
Bowden ChristopherChief Medical OfficerFeb 16Option Exercise35.162,00070,3202,881Feb 20 04:03 PM
Bowden ChristopherChief Medical OfficerFeb 16Sale77.652,000155,305881Feb 20 04:03 PM
Biller ScottChief Scientific OfficerFeb 05Option Exercise8.873,00026,60156,059Feb 07 04:05 PM
Biller ScottChief Scientific OfficerFeb 05Sale76.043,000228,12853,059Feb 07 04:05 PM
Schenkein David PChief Executive OfficerFeb 01Option Exercise0.3013,0003,93313,000Feb 05 04:40 PM
Bowden ChristopherChief Medical OfficerFeb 01Option Exercise35.162,00070,3202,881Feb 05 04:43 PM
Bowden ChristopherChief Medical OfficerFeb 01Sale78.752,000157,500881Feb 05 04:43 PM
Schenkein David PChief Executive OfficerFeb 01Sale78.7513,0001,023,7560Feb 05 04:40 PM
Schenkein David PChief Executive OfficerJan 26Option Exercise0.3023,5727,13123,572Jan 30 04:26 PM
Schenkein David PChief Executive OfficerJan 26Sale81.0923,5721,911,4940Jan 30 04:26 PM
Schenkein David PChief Executive OfficerJan 24Option Exercise0.3020620Jan 26 04:22 PM
Schenkein David PChief Executive OfficerJan 24Option Exercise0.3013,5334,09413,533Jan 25 04:03 PM
Schenkein David PChief Executive OfficerJan 24Sale80.0113,5331,082,7750Jan 25 04:03 PM
Schenkein David PChief Executive OfficerJan 24Sale80.01201,6000Jan 26 04:22 PM
Hoerter Steven L.Chief Commercial OfficerJan 23Option Exercise39.7625,000994,00025,000Jan 25 04:03 PM
Schenkein David PChief Executive OfficerJan 23Option Exercise0.3032,8759,94532,875Jan 25 04:03 PM
CELGENE CORP /DE/10% OwnerJan 23Buy67.00851,15457,027,3181,374,599Jan 23 04:35 PM
Hoerter Steven L.Chief Commercial OfficerJan 23Sale74.8325,0001,870,7500Jan 25 04:03 PM
Schenkein David PChief Executive OfficerJan 23Sale80.0132,8752,630,3290Jan 25 04:03 PM
Schenkein David PChief Executive OfficerJan 16Option Exercise0.3053,00016,03353,000Jan 16 05:16 PM
Schenkein David PChief Executive OfficerJan 16Sale73.1653,0003,877,2180Jan 16 05:16 PM
Alenson CarmanPrincipal Accounting OfficerJan 12Option Exercise52.292,150112,4242,150Jan 26 04:23 PM
Alenson CarmanPrincipal Accounting OfficerJan 12Sale75.002,150161,2500Jan 26 04:23 PM
Biller ScottChief Scientific OfficerJan 10Option Exercise0.473,0001,40356,059Jan 12 04:34 PM
Biller ScottChief Scientific OfficerJan 10Sale65.003,000195,00053,059Jan 12 04:34 PM
Cantley Lewis Clayton Jr.DirectorDec 07Sale60.2191955,33279,515Dec 08 04:23 PM
Cantley Lewis Clayton Jr.DirectorDec 07Sale60.2191955,33279,475Dec 08 04:23 PM
Biller ScottChief Scientific OfficerDec 06Option Exercise1.7446,79581,37653,059Dec 08 04:22 PM
Cantley Lewis Clayton Jr.DirectorDec 06Sale58.601,00058,59780,434Dec 08 04:23 PM
Cantley Lewis Clayton Jr.DirectorDec 06Sale58.601,00058,59680,394Dec 08 04:23 PM
Biller ScottChief Scientific OfficerDec 01Option Exercise31.642,14667,8998,410Dec 05 04:09 PM
Schenkein David PChief Executive OfficerDec 01Option Exercise0.306,0001,8156,000Dec 05 04:28 PM
Schenkein David PChief Executive OfficerDec 01Sale61.556,000369,2880Dec 05 04:28 PM
Biller ScottChief Scientific OfficerDec 01Sale60.792,146130,4596,264Dec 05 04:09 PM
Cantley Lewis Clayton Jr.DirectorNov 14Sale59.701,00059,70081,434Nov 15 05:43 PM
Cantley Lewis Clayton Jr.DirectorNov 14Sale59.701,00059,70081,394Nov 15 05:43 PM
Cantley Lewis Clayton Jr.DirectorNov 13Sale62.071,00062,07082,434Nov 15 05:43 PM
Cantley Lewis Clayton Jr.DirectorNov 13Sale62.071,00062,07082,394Nov 15 05:43 PM
Schenkein David PChief Executive OfficerNov 01Option Exercise0.306,0001,8156,000Nov 03 04:00 PM
Biller ScottChief Scientific OfficerNov 01Option Exercise31.642,14667,8998,410Nov 03 04:01 PM
Biller ScottChief Scientific OfficerNov 01Sale62.692,146134,5226,264Nov 03 04:01 PM
Schenkein David PChief Executive OfficerNov 01Sale63.856,000383,1050Nov 03 04:00 PM
Cantley Lewis Clayton Jr.DirectorOct 17Sale71.101,00071,10083,434Oct 18 05:34 PM
Cantley Lewis Clayton Jr.DirectorOct 17Sale71.101,00071,10083,394Oct 18 05:34 PM
Cantley Lewis Clayton Jr.DirectorOct 16Sale71.091,00071,09084,434Oct 18 05:34 PM
Cantley Lewis Clayton Jr.DirectorOct 16Sale71.091,00071,09084,394Oct 18 05:34 PM
Schenkein David PChief Executive OfficerOct 04Option Exercise0.3080,00024,20080,000Oct 05 06:33 PM